welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
study id #: NCT03532542
condition: Duchenne Muscular Dystrophy
status: enrolling by invitationpurpose:
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
intervention: Casimersen, Golodirsen
mechanism of action: Exon-skipping to promote dystrophin production
last updated: December 04, 2019
start date: August 2, 2018
estimated completion: August 10, 2026
phase of development: Phase 3
size / enrollment: 260
- Number of patients with serious adverse events (SAEs) [Time Frame: Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)]]
• Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
• Is between 7 and 23 years of age, inclusive, at enrollment.
ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular DystrophyThe Institute for Clinical and Economic ...
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular DystrophyDystrophinopathy is a disease continuum ...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular DystrophySarepta Therapeutics, Inc., the leader...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...